Humana Inc vs Nebius Group NV — how do they compare? Humana Inc trades at $445 (market cap $47.61B), while Nebius Group NV trades at $226.74 (market cap $64.47B). The key difference: Nebius Group NV is the larger of the two by market cap, and Humana Inc pays a 0.89% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Nebius Group NV for 24 Days on average.
| HUM | NBIS | |
|---|---|---|
Market Cap | $47.61B | $64.47B |
Volume | 1,827,332 | 17,733,531 |
Sector | Health | Technology |
52-Week High | $409.85 | $286.69 |
52-Week Low | $163.67 | $73.87 |
Typical Hold Time | 53 Days | 24 Days |
Enterprise Value | $54.97B | $66.60B |
Dividend Yield | 0.89% | — |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
NBIS trades at $237.07, down 5.08% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company shows strong revenue growth with $529.8M in 2025 revenue and a $37B backlog, though profitability remains challenged with a net margin of 3.13%. Recent news highlights significant AI infrastructure deals with Meta, Nvidia, and Palantir, while analyst consensus remains strongly bullish with 82% buy ratings.
The outlook for NBIS is growth-focused but carries execution risks. The stock offers substantial upside to the $272.70 consensus target, supported by AI infrastructure demand and strategic partnerships. Key risks include high valuation multiples (P/E 912), negative cash flow from investing activities, and insider selling. Investors should weigh the company's rapid expansion against its current profitability challenges and competitive pressures in the AI cloud sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →